Industry News
13 Nov 2026

New FDA NAION Vision Loss Warning for GLP-1 Receptor Agonists: Key Takeaways for Australian Eyecare Teams

New FDA NAION Vision Loss Warning for GLP-1 Receptor Agonists: Key Takeaways for Australian Eyecare TeamsThe US Food and Drug Administration (FDA) has ordered a class-wide safety labeling update for all glucagon-like peptide-1 receptor agonists (GLP-1 RAs), requiring manufacturers to warn of a potential increased risk of non-arteritic anterior ischaemic optic neuropathy (NAION). 

While the mandate originates in the United States, the ripple effects are highly relevant for Australian optometrists and ophthalmologists, given the explosive prescribing rates of GLP-1 RAs such as semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and tirzepatide (Mounjaro, Zepbound) for type 2 diabetes and weight management locally.

Here is a breakdown of the FDA’s findings, the clinical implications, and how Australian eyecare professionals should respond.

The Evidence Behind the FDA Mandate

The FDA's decision follows a comprehensive evaluation of clinical trial data, postmarketing reports, and observational studies. The agency highlighted a meta-analysis of 126 randomised, controlled clinical trials across multiple GLP-1 RA development programs. 

The data revealed an incidence rate of 6.4 NAION cases per 100,000 person-years in patients treated with GLP-1 RAs, compared to 3.8 cases per 100,000 person-years in patients receiving a placebo or a non-GLP-1 RA glucose-lowering medication. 

While the FDA noted that risk factors for NAION often overlap with conditions common in patients prescribed GLP-1 RAs (such as diabetes, hypertension, and obesity), the agency concluded that a potential increased risk warrants formal inclusion in the Warnings and Precautions section of all product labeling.

Recognising NAION in the Consulting Room

NAION is a rare condition characterised by acute, painless, decreased vision in one eye, which can sometimes result in permanent vision loss. The FDA advises that healthcare professionals instruct patients to report any of the following symptoms immediately:

  • Sudden, painless vision loss or blurring in one eye (often noticed upon waking).
  • Visual field deficits, such as blind spots or altitudinal defects.
  • Distortion of colours or reduced central sharpness.

If NAION is suspected, the FDA recommends prompt referral to an ophthalmologist for comprehensive evaluation, including optic disc assessment and visual field testing.

Australian Clinical Guidance: Vigilance Without Panic

The FDA's move aligns with growing global scrutiny of GLP-1 RAs and ocular health, echoing recent safety updates from the Therapeutic Goods Administration (TGA) regarding a possible link between these medications and NAION.

However, Australian peak bodies are urging a measured, evidence-based response. Both the Royal Australian and New Zealand College of Ophthalmologists (RANZCO) and Optometry Australia (OA) have previously advised that patients should not stop or delay GLP-1 treatment solely due to concerns about NAION. 

This mirrors guidance from the American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society (NANOS), which emphasised that while the FDA's warning is important, NAION remains rare, any added risk appears small, and definitive causation has not been established. 

For patients who do develop NAION while on a GLP-1 RA, the FDA recommends considering discontinuation of the therapy unless the metabolic or weight-loss benefits of the treatment clearly outweigh the risks. This underscores the need for individualised, shared decision-making between the patient, their prescribing GP or endocrinologist, and their eyecare team.

Action Points for Australian Eyecare Professionals

  • Update Medication Histories: Routinely and explicitly ask patients about GLP-1 RA use during comprehensive eye exams, as these medications are increasingly prescribed in the community.
  • Patient Education: Briefly counsel patients on GLP-1 RAs about the symptoms of NAION. Emphasise that while the risk is rare, sudden, painless vision loss requires immediate emergency eyecare assessment.
  • Low Threshold for Referral: Maintain a high index of suspicion for NAION in patients presenting with acute, painless monocular vision loss, particularly if they have vascular risk factors and are using GLP-1 RAs.
  • Interprofessional Communication: If NAION is diagnosed or suspected in a patient taking a GLP-1 RA, promptly communicate your findings to the patient’s prescribing medical practitioner to facilitate collaborative, shared decision-making regarding the continuation of the drug.

Disclaimer: This article is for informational purposes for healthcare professionals and does not constitute formal medical or legal advice. Practitioners should refer to the latest TGA guidelines and RANZCO/Optometry Australia clinical statements for local practice standards.